Abstract
Background
Several factors, which are components of pharmaceutical care, can influence a patient’s choice of a community pharmacy store and contribute to frequent visits to the same pharmacy.
Objectives
To compare factors that influence a patient’s choice of pharmacy in Poland and in the UK, to identify which of them are components of pharmaceutical care, and to relate them to patient loyalty to the same pharmacy.
Methods
A self-administered, anonymous questionnaire was distributed to clients visiting pharmacies in Poland and the UK January–August 2011. Comparisons were performed using chi-square tests and logistic regression. All statistical analyses were performed using SPSS 20.0.
Results
The response rate was 55.6% (n=417/750; 36 pharmacies) and 54.0% (n=405/750; 56 pharmacies) in Poland and in the UK, respectively. The most frequently reported factors, as defined by a percentage of responders, were in Poland: 1) location (84%); 2) professional and high-quality of service (82%); 3) good price of medicines (78%); and 4) promotions on medicines (66%). In the UK, the most commonly reported factors were: 1) professional and high quality of service (90%); 2) location (89%); 3) good advice received from the pharmacist (86%); and 4) option of discussing and consulting all health issues in a consultation room (80%). Good advice and an option of discussing personal concerns with a pharmacist are components of pharmaceutical care. Thirty-eight percent of patients in Poland and 61% in the UK declared visiting the same pharmacy.
Conclusion
Components of pharmaceutical care are important factors influencing the patient’s choice of pharmacy in the UK and, to a lesser degree, in Poland. Additionally, more patients in the UK than in Poland are committed to a single pharmacy. Therefore, implementing the full pharmaceutical care in Poland may contribute to an increase in patient loyalty and thus strengthen competitiveness of pharmacy businesses.
Acknowledgments
We wish to express our sincere appreciation and thanks to the following organizations for providing their help and guidance at every stage of our research: the Royal Pharmaceutical Society (UK); the Pharmaceutical Services Negotiating Committee (UK); the Department of Health (UK); and the Polish Pharmaceutical Society (Poland). We would also like to thank Bjorn Jonsson, Department of Women’s and Children’s Health, Uppsala University (Uppsala, Sweden), for the statistical expertise and statistical analysis, and Izabela Zdolińska-Malinowska of Proper Medical Writing (Warsaw, Poland) for formatting the final version of our manuscript.
Disclosure
The authors report no conflicts of interest in this work.